Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy
ConclusionsFrom our data we conclude that post-nCT miR-18a expression in breast cancer serves as a negative prognostic marker, especially in luminal tumors. Clinical, in vitro and in silico data support the role of miR-18a in breast cancer cell proliferation and endocrine resistance and suggest its potential utility as a biomarker for additional adjuvant treatment in patients without a pathologic complete response to neoadjuvant therapy.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Genetics | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Tamoxifen